Trial Profile
Leuprolide Acetate (LHRH Agonist) to Enhance Immune Function Post-Autologous Stem Cell Transplantation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; Keyhole limpet haemocyanin
- Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
- Sponsors Abbott Laboratories; TAP Pharmaceutical Products
- 11 May 2010 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Sep 2008 Sponsor and collaborator changed from TAP Pharmaceuticals to Abbott Laboratories according to ClinicalTrials.gov.